You are here

Article Text

Article menu
Download PDFPDF
Case report
Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody
  1. Cornelis K van der Ent1,
  2. Hans Hoekstra2,
  3. Ger T Rijkers3
  1. 1Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
  2. 2Department of Pediatrics, Hieronymus Bosch Hospital, Hertogenbosch, The Netherlands
  3. 3Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  1. Correspondence to:
    Dr C K van der Ent
    Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, KH 01.419.0, PO Box 85090, 3508 AB Utrecht, The Netherlands; k.vanderent{at}wkz.azu.nl

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.

https://doi.org/10.1136/thx.2004.035519

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text